Next Biomedical Co.,Ltd. (KOSDAQ:389650)
South Korea · Delayed Price · Currency is KRW 72,400
-3,600 (-4.74%)
At close: Feb 6, 2026
Next Biomedical Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Operating Revenue | 14,905 | 9,543 | 4,882 | 2,795 | 2,267 | 2,261 |
Other Revenue | - | - | - | -0 | - | -0 |
| 14,905 | 9,543 | 4,882 | 2,795 | 2,267 | 2,261 | |
Revenue Growth (YoY) | 70.64% | 95.46% | 74.67% | 23.28% | 0.29% | 182.32% |
Cost of Revenue | 4,819 | 3,787 | 2,813 | 2,618 | 2,998 | 2,433 |
Gross Profit | 10,085 | 5,755 | 2,069 | 177.49 | -731.09 | -172.71 |
Selling, General & Admin | 4,208 | 2,610 | 2,407 | 2,246 | 2,866 | 1,994 |
Research & Development | 7,172 | 6,622 | 4,783 | 3,579 | 3,245 | 2,720 |
Amortization of Goodwill & Intangibles | 13.71 | 22.71 | 31.02 | 34.25 | 31.6 | 23.72 |
Other Operating Expenses | 26.16 | 21.51 | 20.04 | 19.29 | 18.39 | 10.61 |
Operating Expenses | 11,476 | 9,330 | 7,296 | 5,946 | 6,239 | 4,832 |
Operating Income | -1,391 | -3,575 | -5,226 | -5,768 | -6,970 | -5,004 |
Interest Expense | -421.68 | -520.06 | -574.37 | -360.41 | -1,413 | -1,535 |
Interest & Investment Income | 939.93 | 634.82 | 574.31 | 200.41 | 138.66 | 35.87 |
Currency Exchange Gain (Loss) | 751.36 | 1,128 | 0.56 | 63.63 | 90.33 | -77.31 |
Other Non Operating Income (Expenses) | -53.28 | 5,074 | -2,429 | 268.61 | -8,494 | -17,835 |
EBT Excluding Unusual Items | -174.58 | 2,742 | -7,655 | -5,596 | -16,648 | -24,416 |
Gain (Loss) on Sale of Investments | 47.02 | 113.58 | 133.56 | -102.48 | -65.86 | -34.61 |
Gain (Loss) on Sale of Assets | 9.78 | 4.24 | - | 5.29 | 69.58 | 0.1 |
Asset Writedown | - | - | - | -38.72 | -0.8 | -27.31 |
Pretax Income | -117.78 | 2,860 | -7,522 | -5,732 | -16,645 | -24,477 |
Net Income | -117.78 | 2,860 | -7,522 | -5,732 | -16,645 | -24,477 |
Net Income to Common | -117.78 | 2,860 | -7,522 | -5,732 | -16,645 | -24,477 |
Shares Outstanding (Basic) | 8 | 7 | 6 | 6 | 5 | 4 |
Shares Outstanding (Diluted) | 8 | 7 | 6 | 6 | 5 | 4 |
Shares Change (YoY) | 19.72% | 17.78% | 1.10% | 28.34% | 13.05% | 199.99% |
EPS (Basic) | -14.53 | 396.71 | -1198.00 | -923.00 | -3440.00 | -5719.00 |
EPS (Diluted) | -606.21 | -262.00 | -1198.00 | -923.00 | -3440.00 | -5719.00 |
Free Cash Flow | -4,083 | -1,640 | -4,225 | -8,403 | -6,101 | -4,003 |
Free Cash Flow Per Share | -503.64 | -221.77 | -672.87 | -1353.18 | -1260.87 | -935.17 |
Gross Margin | 67.67% | 60.31% | 42.38% | 6.35% | -32.25% | -7.64% |
Operating Margin | -9.33% | -37.46% | -107.05% | -206.37% | -307.42% | -221.36% |
Profit Margin | -0.79% | 29.97% | -154.06% | -205.07% | -734.13% | -1082.74% |
Free Cash Flow Margin | -27.40% | -17.18% | -86.53% | -300.65% | -269.08% | -177.05% |
EBITDA | -869.58 | -3,082 | -4,759 | -5,305 | -6,537 | -4,431 |
EBITDA Margin | -5.83% | -32.30% | -97.48% | -189.79% | -288.30% | -195.98% |
D&A For EBITDA | 521.33 | 492.36 | 467.32 | 463.41 | 433.53 | 573.79 |
EBIT | -1,391 | -3,575 | -5,226 | -5,768 | -6,970 | -5,004 |
EBIT Margin | -9.33% | -37.46% | -107.05% | -206.37% | - | -221.36% |
Advertising Expenses | - | 171.98 | 196.9 | 59.64 | 76.25 | 8 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.